Abstracts

PHARMACOKINETICS AND VIROLOGIC OUTCOMES OF BICTEGRAVIR IN PREGNANCY AND POSTPARTUM

Background: Bictegravir (BIC) is an HIV-1 integrase strand transfer inhibitor with potent antiviral activity. It is highly protein bound (~99.7%) and eliminated by UGT1A1 and CYP3A metabolism. Although protein binding and hepatic enzyme activity are altered during pregnancy, limited data exist on BIC pharmacokinetics (PK) in pregnancy. We describe preliminary BIC PK in pregnancy compared…

PrEP PRESCRIPTIONS AMONG PERSONS WITH MEDICAID BY RACE AND ETHNICITY: UNITED STATES

Background: Black/African American (Black) and Hispanic or Latino (Hispanic) populations have high HIV incidence but low coverage of preexposure prophylaxis (PrEP) prescriptions among those with PrEP indications. Pharmacy data are used to monitor the effectiveness of programmatic activities to decrease racial/ethnic disparities in PrEP use. These data are missing race/ethnicity variables for about 70% of…

PREGNANCY HORMONAL DYSREGULATION CORRELATES WITH HIV-EXPOSED INFANT GROWTH OUTCOMES

Background: Many hormones in pregnancy regulate fetal growth. Few data exist on fetal growth-related hormones in pregnancy in women living with HIV (WLHIV) and whether maternal hormonal alterations are associated with infant anthropometrics. Methods: The Tshilo Dikotla study prospectively enrolled pregnant women in Botswana. WLHIV receiving dolutegravir/tenofovir/emtricitabine and HIV-seronegative (HIV-) women were included in this…

PRE-EXPOSURE PROPHYLAXIS PRODUCT CHOICE IN US PARTICIPANTS IN HPTN 083

Background: HPTN 083 demonstrated superiority of long-acting injectable cabotegravir (CAB-LA) compared to daily oral tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) for HIV pre-exposure prophylaxis (PrEP) in cisgender men and transgender women (TGW) who have sex with men. At a planned interim review, an independent data safety and monitoring board recommended the study be unblinded. The protocol was…

SYSTEMIC INFLAMMATION, GUT DYSBIOSIS AND GUT MICROBIOME IMPACT HIV MIGRATION DYNAMICS

Background: HIV persists in the human body, including the gastrointestinal (GI) tract where the virus causes cellular damage, microbial translocation and inflammation. The GI tract also act as a source of rebounding virus upon cessation of ART. We investigate HIV dynamics within host between tissue reservoirs and evaluate biomarkers, viral reservoir characteristics and microbiome composition…